Hepatitis B

J&J partners with startup for DNA vaccine, hand-held device to treat HBV in $85M+ deal

Janssen Pharmaceuticals has paired up with Ichor Medical Systems to develop and market DNA-based vaccine products to treat chronic hepatitis B (HBV). The partners will use the startup's TriGrid electroporation technology for clinical administration of a DNA vaccine.

La confiance des médecins dans la vaccination, point clef pour l'application des recommandations vaccinales

Ces dernières années, un accroissement préoccupant d'opinions défavorables à la vaccination a été constaté dans la population générale en France. Plusieurs controverses ont eu lieu depuis la fin des années 1990 :
  • maladies neurodégénératives et vaccination contre l'hépatite B,
  • remise en cause de la vaccination contre la grippe pandémique A(H1N1)pdm09,
  • plaintes pénales à propos d'événements indésirables attribués à la vaccination contre les papillomavirus,
  • mise en cause de l'aluminium présent dans certains vaccins.

As WHO drafts its global health strategies, a need to reconsider viral hepatitis response

The World Health Organization recently announced that it was seeking input on the three global health sector strategies — HIV and AIDS, viral hepatitis and sexually transmitted infection — it was drafting until April 30. The strategies, which will cover 2016-2021, will be finalized at the 69th World Health Assembly in 2016.

HBV: React Before the Virus Does

Let me begin by paraphrasing Santayana: "Those who cannot recognize the past are condemned to repeat it."
I refer specifically to the importance of recognizing past infection with the hepatitis B virus (HBV) to forestall reactivation of clinically significant viral hepatitis during immunosuppressive therapy.

Immunization coverage

Key facts
  • Immunization prevents illness, disability and death from vaccine-preventable diseases including cervical cancer, diphtheria, hepatitis B, measles, mumps, pertussis, pneumonia, polio, rotavirus diarrhoea, rubella and tetanus.
  • Global vaccination coverage is holding steady.
  • Immunization currently averts an estimated 2 to 3 million deaths every year.
  • But an estimated 21.8 million infants worldwide are still missing out on basic vaccines.

New progress with oral hepatitis B vaccine

Researchers from Applied Biotechnology Institute and Iowa State University have made progress in developing an oral hepatitis B vaccine delivered via genetically modified corn that would require no refrigeration and cost less than $1 per dose to manufacture.
The majority of vaccines that are created are developed with inactivated or weakened pathogens made with eggs, but the new vaccine uses genetically modified corn to create virus-like hepatitis B particles that are non-infectious.

Tensions d’approvisionnement des vaccins contre la coqueluche : adaptation de la stratégie vaccinale

Le Haut Conseil de santé publique (HCSP) vient de publier un avis sur l'adaptation de la stratégie vaccinale face aux difficultés d'approvisionnement des vaccins combinés contenant la valence coqueluche (avis du 25 février 2015).

Protection Without a Vaccine

Last month, a team of scientists announced what could prove to be an enormous step forward in the fight against H.I.V.
Scientists at Scripps Research Institute said they had developed an artificial antibody that, once in the blood, grabbed hold of the virus and inactivated it. The molecule can eliminate H.I.V. from infected monkeys and protect them from future infections.